Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)

Biotronik SE & Co. KG167 enrolled

Overview

This study is a post-market clinical follow-up (PMCF) study to identify and evaluate residual risks associated with the use of the BIOMONITOR III and BIOMONITOR IIIm that are discovered or remain even after risk analysis, risk mitigation and successful conformity assessment. Furthermore, this study will also provide additional data as required by regulatory authorities outside of the CE-region.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

167

Conditions

Tachyarrhythmia Atrial Fibrillation (AF)Syncope Cryptogenic Stroke

Interventions

BIOMONITOR III and BIOMONITOR IIImDEVICE

* Insertion of BIOMONITOR III or BIOMONITOR IIIm * three scheduled in-office follow-ups * 48-hour Holter ECG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient is at high risk of developing a clinically important cardiac arrhythmia; or * Patient is undergoing investigation for symptoms such as palpitations, pre- syncope or syncope, that are suggestive of an underlying cardiac arrhythmia; or * Patient is undergoing investigation for the detection of atrial fibrillation following cryptogenic stroke; or * Patient is planned for AF ablative procedure or has already undergone an AF ablative procedure. * Patient is able to understand the nature of the study and able to provide written informed consent. * Patient is willing and able to perform all follow-up visits at the investigational site. * Patient is willing and able to use the CardioMessenger and accepts the BIOTRONIK Home Monitoring concept. Exclusion Criteria: * Patient is implanted with an ICD or pacemaker. * Patient is pregnant or breast-feeding. * Patient is less than 18 years old. * Patient's life-expectancy is less than 12 months. * Patient is participating in another interventional clinical investigation.

Locations (27)

GenesisCare Wesley

Auchenflower, Australia

Outcomes

Primary Outcomes

SADE-free Rate Until the 3-month Follow-up

SADE-free rate related to BIOMONITOR III and BIOMONITOR IIIm including incision and insertion tool set until 3-month follow-up

Time frame: 3 months

Secondary Outcomes

R-wave Amplitude

The secondary endpoint 1 evaluates the R-wave amplitude at the 1st follow-up and at 3-month follow-up by measuring both, the lowest and the highest amplitude value via the programmer.

Time frame: 10 days to 4 weeks after insertion; 3-months

Noise Burden

The secondary endpoint 2 evaluates the noise burden at the 1st follow-up and at 3-month follow-up by retrieving the percentage of noise via the programmer.

Time frame: 10 days to 4 weeks after insertion; 3-months

Assessment of P-wave Visibility

The secondary endpoint 3 evaluates the P-wave visibility at 1st, 3- and 12-month follow-up. The investigator will evaluate whether P-waves can be recognized in the stored sECGs showing sinus rhythm. The number of heart cycles and observed P-waves which can undoubtly be identified in ECGs will be assessed by the investigator.

Time frame: 10 days to 4 weeks after insertion; 3-months

SADE-free Rate Until the 12-month Follow-up

The secondary endpoint 4 is the SADE-free rate related to the BIOMONITOR III and BIOMONITOR IIIm 12 months after insertion.

Time frame: 12-months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.